This is a renewal of a Program Project Grant whose original goal was to use genetically altered animals to understand significant aspects of lipoprotein metabolism and vascular biology. Our goals remain the same, but our objectives in lipoprotein physiology are now more tightly focused on one of the strengths of the Institute, i.e., the understanding of the physiological functions of apolipoprotein (apo-) E and apo-B. In addition, we now have a major new emphasis in vascular biology and vascular gene therapy. The research focuses on the metabolic and mechanistic consequences of the expression, modification, or deletion of key molecules on lipoprotein metabolism, intracellular metabolism, vascular wall remodeling, and atherosclerosis. The key molecules that will be investigated in lipoprotein transport and metabolism are apo-E and apo-B. In intracellular biosynthesis and catabolism of lipoprotein, these molecules include APOBEC-1 (the enzyme responsible for apo-B mRNA-editing), microsomal triglyceride transfer protein, and the low density lipoprotein receptor-related protein; and in cell and vascular wall metabolism, they are NTA1 (novel target for APOBEC-I) and transforming growth factor (31. While transgenic animals, knockout mice, and somatic gene altered animals are the main model systems, many other intact cell and cell-free model systems will be employed. In addition, a wide variety of techniques will be used, including those from the disciplines of biochemistry, molecular biology, genetics, cell biology, animal physiology, and microscopy. New technologies are shared among the projects and are provided by the Transgenic Animal Core and by the Metabolism and Pathology Core, which are heavily used by all of the projects. The successful completion of this program project will enhance the understanding of fundamental mechanisms of lipoprotein metabolism and vascular wall biology.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL047660-09
Application #
6183666
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
1992-09-30
Project End
2002-08-31
Budget Start
2000-09-01
Budget End
2001-08-31
Support Year
9
Fiscal Year
2000
Total Cost
$1,430,113
Indirect Cost
Name
J. David Gladstone Institutes
Department
Type
DUNS #
047120084
City
San Francisco
State
CA
Country
United States
Zip Code
94158
Zhang, Songwen; Picard, Michael H; Vasile, Eliza et al. (2005) Diet-induced occlusive coronary atherosclerosis, myocardial infarction, cardiac dysfunction, and premature death in scavenger receptor class B type I-deficient, hypomorphic apolipoprotein ER61 mice. Circulation 111:3457-64
Raffai, Robert L; Loeb, Samuel M; Weisgraber, Karl H (2005) Apolipoprotein E promotes the regression of atherosclerosis independently of lowering plasma cholesterol levels. Arterioscler Thromb Vasc Biol 25:436-41
Huang, Yadong; Weisgraber, Karl H; Mucke, Lennart et al. (2004) Apolipoprotein E: diversity of cellular origins, structural and biophysical properties, and effects in Alzheimer's disease. J Mol Neurosci 23:189-204
Raffai, Robert L; Hasty, Alyssa H; Wang, Yuwei et al. (2003) Hepatocyte-derived ApoE is more effective than non-hepatocyte-derived ApoE in remnant lipoprotein clearance. J Biol Chem 278:11670-5
Hersberger, Martin; Patarroyo-White, Susannah; Qian, Xiaobing et al. (2003) Regulatable liver expression of the rabbit apolipoprotein B mRNA-editing enzyme catalytic polypeptide 1 (APOBEC-1) in mice lacking endogenous APOBEC-1 leads to aberrant hyperediting. Biochem J 369:255-62
Aiyagari, Abigail L; Taylor, Brigit R; Aurora, Vikas et al. (2003) Hematologic effects of inactivating the Ras processing enzyme Rce1. Blood 101:2250-2
Raffai, Robert L; Weisgraber, Karl H (2002) Hypomorphic apolipoprotein E mice: a new model of conditional gene repair to examine apolipoprotein E-mediated metabolism. J Biol Chem 277:11064-8
Ludwig, Erwin H; Mahley, R W; Palaoglu, E et al. (2002) DGAT1 promoter polymorphism associated with alterations in body mass index, high density lipoprotein levels and blood pressure in Turkish women. Clin Genet 62:68-73
Ji, Zhong-Sheng; Miranda, R Dennis; Newhouse, Yvonne M et al. (2002) Apolipoprotein E4 potentiates amyloid beta peptide-induced lysosomal leakage and apoptosis in neuronal cells. J Biol Chem 277:21821-8
Boren, J; Ekstrom, U; Agren, B et al. (2001) The molecular mechanism for the genetic disorder familial defective apolipoprotein B100. J Biol Chem 276:9214-8

Showing the most recent 10 out of 72 publications